Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.

Gallay PA, Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z.

PLoS One. 2016 Apr 22;11(4):e0152036. doi: 10.1371/journal.pone.0152036. eCollection 2016.

2.

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, Foster R.

PLoS One. 2015 Aug 11;10(8):e0134707. doi: 10.1371/journal.pone.0134707. eCollection 2015.

3.

HCV core residues critical for infectivity are also involved in core-NS5A complex formation.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA.

PLoS One. 2014 Feb 12;9(2):e88866. doi: 10.1371/journal.pone.0088866. eCollection 2014.

4.

Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B.

Viruses. 2013 Mar 22;5(3):981-97. doi: 10.3390/v5030981.

5.

Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.

Gunaseelan S, Gallay PA, Bobardt MD, Dezzutti CS, Esch T, Maskiewicz R.

Pharm Res. 2012 Nov;29(11):3156-68. doi: 10.1007/s11095-012-0811-8. Epub 2012 Jun 27. Erratum in: Pharm Res. 2013 Mar;30(3):911.

6.

HSV neutralization by the microbicidal candidate C5A.

de Witte L, Bobardt MD, Chatterji U, van Loenen FB, Verjans GM, Geijtenbeek TB, Gallay PA.

PLoS One. 2011 May 6;6(5):e18917. doi: 10.1371/journal.pone.0018917.

7.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

8.

Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Bobardt MD, Chatterji U, Schaffer L, de Witte L, Gallay PA.

Antimicrob Agents Chemother. 2010 Jul;54(7):2753-66. doi: 10.1128/AAC.01606-09. Epub 2010 May 3.

9.

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Chatterji U, Bobardt MD, Lim P, Gallay PA.

J Gen Virol. 2010 May;91(Pt 5):1189-93. doi: 10.1099/vir.0.018531-0. Epub 2010 Jan 27.

10.

Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.

Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5525-30. doi: 10.1073/pnas.0801388105. Epub 2008 Mar 31.

11.

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, de Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B.

Antimicrob Agents Chemother. 2008 Apr;52(4):1302-17. doi: 10.1128/AAC.01324-07. Epub 2008 Jan 22.

12.

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells.

Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, Kahn B, Gallay PA.

J Virol. 2007 Jan;81(1):395-405. Epub 2006 Oct 18.

13.

Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.

Chatterji U, Bobardt MD, Gaskill P, Sheeter D, Fox H, Gallay PA.

J Biol Chem. 2006 Dec 1;281(48):37025-33. Epub 2006 Oct 6.

14.

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells.

Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, Jones MJ, Stoddart CA, Scalfaro P, Dumont JM, Besseghir K, Rosenwirth B, Gallay PA.

J Biol Chem. 2005 Dec 2;280(48):40293-300. Epub 2005 Sep 30.

15.

A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.

de Parseval A, Bobardt MD, Chatterji A, Chatterji U, Elder JH, David G, Zolla-Pazner S, Farzan M, Lee TH, Gallay PA.

J Biol Chem. 2005 Nov 25;280(47):39493-504. Epub 2005 Sep 12.

16.

Effect of polyanion-resistance on HIV-1 infection.

Bobardt MD, Armand-Ugón M, Clotet I, Zhang Z, David G, Este JA, Gallay PA.

Virology. 2004 Aug 1;325(2):389-98.

17.

Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion.

Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA.

J Virol. 2004 Jun;78(12):6567-84.

18.

Syndecan captures, protects, and transmits HIV to T lymphocytes.

Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA.

Immunity. 2003 Jan;18(1):27-39.

21.

Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.

Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA.

J Virol. 2001 Oct;75(19):9187-200.

22.

Human immunodeficiency virus type 1 hijacks host cyclophilin A for its attachment to target cells.

Saphire AC, Bobardt MD, Gallay PA.

Immunol Res. 2000;21(2-3):211-7. Review.

PMID:
10852119
23.

Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.

Saphire AC, Bobardt MD, Gallay PA.

EMBO J. 1999 Dec 1;18(23):6771-85.

24.

Selective modulation of elements of the immune system by low molecular weight nucleosides.

Goodman MG, Reitz AB, Chen R, Bobardt MD, Goodman JH, Pope BL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1552-7.

PMID:
7562533

Supplemental Content

Loading ...
Support Center